Probiotics in digestive, emotional, and pain-related disorders by Roman, Pablo et al.
 "2018 Special Issue: Behavioural pharmacology and brain–body signalling processes"  
 
Title: Probiotics in digestive, emotional and pain-related disorders. 
Authors: Pablo Roman1,2, Raquel Abalo3, Eva M. Marco4, and Diana Cardona1. 
Affiliations: 
1. Departamento de Enfermería, Fisioterapia y Medicina, Universidad de Almería, 
La Cañada, 04120 Almería, Spain. 
2. Departamento de Enfermería, Universitat Jaume I, Avenida de Vicent Sos 
Baynat, s/n, 12071 Castellón de la Plana, Castellón, Spain.  
3. Área de Farmacología y Nutrición, Departamento de Ciencias Básicas de la 
Salud, Universidad Rey Juan Carlos (URJC), 28922 Alcorcón, Spain; Unidad 
Asociada I+D+i del Instituto de Química Médica (IQM), Consejo Superior de 
Investigaciones Científicas (CSIC), Madrid, Spain.; Unidad Asociada I+D+i del 
Instituto de Investigación en Ciencias de la Alimentación (CIAL), Consejo 
Superior de Investigaciones Científicas (CSIC), Madrid, Spain; Grupo de 
Excelencia Investigadora URJC-Banco de Santander-Grupo multidisciplinar de 
investigación y tratamiento del dolor (i+DOL), Alcorcón, Spain. 
4. Departamento de Fisiología (Fisiología Animal II), Facultad de Biología, 




Roman et al.  Probiotics in digestive, emotional and pain-related disorders 
 2 
Abstract 
In the recent years, interest on the relationship between gut microbiota and disease 
states has grown considerably. Indeed, several strategies have been employed to 
modify the microbiome through the administration of different diets, by the 
administration of antibiotics or probiotics, or even by transplants of faeces. In the 
present manuscript we will specifically focus on the potential application of probiotics, 
which seem as a safe strategy, in the management of digestive, pain and emotional 
disorders. Herein, we will present evidence from animal models and human studies, 
despite the translation to the clinic still deserves further investigation. Microbiome 
influences gut functions as well as neurological activity by a variety of mechanisms that 
will also be discussed. The design and performance of larger trials is urgently needed 
to verify whether these new strategies might be useful not only for the treatment of 
disorders affecting the gastrointestinal tract but also in the management of emotional 
and pain disorders not directly related to the gut. 
 
 
Keywords: Gut microbiota, probiotics, gastrointestinal disorders, pain, emotion, 
animal models, human studies.  
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1. THE MICROBIOTA-GUT-BRAIN AXIS 
The gastrointestinal (GI) tract has been described to be home to more than 100 trillion 
microscopic bacteria (1014 or 100,000,000,000,000 cells) and to host more than 70% of 
all bodily flora (Vyas and Ranganathan, 2012). The collection of microorganisms 
colonizing the GI tract is termed the “gut microbiota” (Bäckhed et al., 2005; Neish, 
2009), and is mainly comprised of bacteria (Balzola et al., 2010; Guarner, 2005). 
Frequently, the importance of gut microbiota has been related to the extended belief 
that bacteria residing in the human body outnumber human cells by a factor of 10 or 
more (10:1 ratio); however, a recent research has updated this ratio to closer to 1:1 
although such a change in numbers should not change the importance of host-
microbiota interactions (Sender et al., 2016). 
The gut is colonized by bacteria from birth, and rapidly reaches concentrations 
up to 1012 organisms per gram of luminal contents in the colon (Ohland and Jobin, 
2015). Composition of microbiota in the infant depends on different factors, like the 
type of delivery (vaginal or cesarean), diet (breast milk or formula), or exposure to 
antibiotics. It is worth mentioning that the gut microbiome contributes to the early 
programming of epithelial barrier function, angiogenesis, and innate and host immune 
function (Rodríguez-Fandiño et al., 2010), and evidences from experimental and 
clinical studies give support to the fact that alterations in the pattern of GI colonization 
have long-term consequences on immune function. After weaning, microbiome 
composition changes and by 2 years of age it is similar to that of adults (Salazar et al., 
2014). The adult microbiome includes approximately 30 species of Bifidobacterium, 52 
species of Lactobacillus, and others, such as Streptococcus and Enterococcus (Wallace 
et al., 2011). In each region of the gut different microorganisms are found. Thus, gram-
positive facultative anaerobic bacteria predominate in the proximal small intestine and 
gram-negative anaerobes in its distal part, whereas in the colon, obligate anaerobes 
outnumber facultative anaerobes. The gut microbiota produces many metabolic 
substances, that depend on each individual’s microbiome and are critically affected by 
the individual’s diet (Blaut and Clavel, 2007); microbiome-released metabolites may 
include several vitamins (folate, biotin), short chain fatty acids (propionate, butyrate, 
acetate) and neuroactive metabolites (serotonin, gamma-butyric acid), among others 
(Sharon et al., 2014). 
Roman et al.  Probiotics in digestive, emotional and pain-related disorders 
 4 
The gut microbiota has been described to exert a profound influence on brain 
physiology and behaviour (Borre et al., 2014; Carabotti et al., 2015; Cryan and Dinan, 
2012; Dinan et al., 2014) through a variety of mechanisms (Chichlowski and Rudolph, 
2015). Locally, bacterial products promote myoelectric activity, activate the enteric 
nervous system (ENS), and stimulate primary afferent nerves (Al-Nedawi et al., 2015; 
Husebye et al., 1994). Furthermore, circulating bacterial metabolites seem to mediate 
changes in behaviour (Chichlowski and Rudolph, 2015). But, at the same time, 
microbiome can also be affected by stress exposure, thus suggesting a bidirectional 
communication at the brain-gut axis.  
Despite intestinal microbiome is considerably stable over time and quite 
resistant to transient aggression, several GI pathologies have been related to changes 
in the stability, diversity, composition, and/or metabolism of gut bacteria; this kind of 
change in the microbiome is known as dysbiosis (Chassard et al., 2012; Mättö et al., 
2005; Rajilić-Stojanović et al., 2011). Interestingly, maintenance and restoration of a 
suitable intestinal microbiota may prevent the development of various diseases, such 
as allergies, obesity and GI diseases, among others (Martin and Kochhar, 2015). 
Actually, gut microbiota has arisen as a remarkable symbiotic partner critical for the 
maintenance of good health (Fond et al., 2015).  
During the last decades, interest on the relationship between gut microbiota 
and disease states has grown considerably. Microbiota has become the focal point of 
research in relation to several pathological conditions including digestive diseases, 
emotional and pain-related disorders (Mayer et al., 2015). Indeed, several strategies 
have been developed to change, both qualitative and/or quantitatively, the 
microbiome; mainly, the reduction of gut microbiota by the administration of 
antibiotics, and its enhancement by the administration of probiotics, or even by faecal 
transplants (Martin & Kochhar, 2015; Fond et al., 2015). Herein, among the several 
strategies available, we will focus on the use of probiotics, in both human and animal 
models, to modify gut microbiota. 
 
2. PROBIOTICS 
Probiotics are defined by the Food and Agriculture Organization (FAO) and the 
International Scientific Association for Probiotics and Prebiotics as “live 
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microorganisms that, when administered in adequate amounts, confer a health benefit 
on the host” (Hill et al., 2014). Historically, the concept of probiotics began around 
1900 by the Nobel laureate Elie Metchnikoff, who discovered that the consumption of 
live bacteria (Lactobacillus bulgaricus) in yogurt or fermented milk improved the 
biological features of the GI tract (Mackowiak, 2013).  
Most commonly used probiotics are lactic acid bacteria, namely from the 
genera Lactobacillus and Bifidobacterium, but also yeasts such as Saccharomyces 
boulardii. These species are non-pathogenic and can resist the harsh luminal 
environment of the GI tract (Bezkorovainy, 2001). Probiotic consumption is reported to 
exert a myriad of positive effects including: enhanced immune response, balancing the 
colonic microbiota, vaccine adjuvant effects, reduction of faecal enzymes implicated in 
cancer initiation, treatment of diarrhoea associated with travelling and antibiotic 
therapy, control of rotavirus and Clostridium difficile-induced colitis and prevention of 
ulcers related to Helicobacter pylori (Kaur, Chopra, & Saini, 2002; Khoder et al, 2016) 
and even, some probiotics have been described as protective against heavy metal 
exposure (Ojekunle et al., 2017). Beneficial effects of probiotics are mediated by 
different mechanisms including competition against pathogenic bacteria in their 
binding to the intestinal epithelial cells, enhancement of intestinal epithelial barrier 
function, inhibition of the growth of pathogens by secreting antimicrobial peptides, 
and/or enhancement of serum IgA production, among others (reviewed in Hardy, 
Harris, Lyon, Beal, & Foey, 2013; Upadhyay & Moudgal, 2012).  
To guarantee probiotics survival, microencapsulated or coated probiotic strains 
are sometimes required (Haghshenas et al., 2015; Kailasapathy, 2002; Nami et al., 
2017). Remarkably, a newer generation of probiotics is based on their capacity to form 
biofilms and on the advances of these probiotics encapsulation techniques (Salas-Jara 
et al., 2016). Occasionally, non-living probiotic strains, known as “para-probiotics” or 
“ghost probiotics”, have also been employed (Adams, 2010; Taverniti and Guglielmetti, 
2011). Actually, these non-viable probiotics, resulting from exposure to high 
temperatures or irradiation, or some probiotic fractions, such as DNA, have been 
shown to induce immune system stimulation against vancomycin-resistant enterococci 
(Sakai et al., 2006), have been reported to enhance TNF-α and IL-6 production (Marin 
et al., 1997), to protect immune-deficient mice against Candida albicans (Wagner et 
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al., 2000), to improve the anti-inflammatory response in rats with experimentally-
induced colitis (Rachmilewitz et al., 2004) and to exert anti-proliferative and pro-
apoptotic effects on cancer cells (Orlando et al., 2012). 
Prebiotics are non-digestible foods that stimulate the growth and/or activity of 
bacteria in the GI. Some prebiotics, such as fructo-oligosacharides and galacto-
oligosaccharides, are anaerobically fermented into short-chain fatty acids (SCFAs) 
(reviewed in Hardy et al., 2013). Accordingly, some recent studies have provided 
further evidence for prebiotics to affect anxiety, learning and memory although data 
from human studies are still limited (Burokas et al., 2017; Kao et al., 2016).  
Alternative designs for using probiotics are being explored and have been 
sometimes gathered under the term “pharmabiotics”. Pharmabiotics encompasses a 
broader set of substances, including live and dead microbes, microbial components, 
and microbe-produced substances (Patterson et al., 2014; Shanahan and Collins, 
2010). Moreover, some genetically modified probiotic strains have been designed to 
be used as vectors for targeted delivery of anti-inflammatory cytokines, vaccines and 
anti-pathogenic molecules, and have been also refereed as “immunobiotics” 
(Shigemori and Shimosato, 2017). 
Herein, in the present review we will present and discuss the most remarkable 
data from animal studies and clinical trials that have analysed the effects of probiotics 
on digestive disorders, emotional and pain-related illnesses. 
 
3. APPLICATION OF PROBIOTICS IN THE MANAGEMENT OF DIGESTIVE DISORDERS 
The list for GI disorders that may be responsive to probiotics is huge (see (Khoder et 
al., 2016) and references provided therein). The use of probiotics as supplements or 
alternatives to oral antibiotic therapy in the treatment of GI infectious diseases [i.e., 
those produced by H. pylori, Salmonella or Clostridium difficile, see (Salas-Jara et al., 
2016)] is very interesting because they may restore the normal microflora, compete 
with the pathogenic resistant bacteria and help patients to recover. Probiotics may 
avoid the use of antimicrobials or reduce the secondary effects associated to their use, 
such as antibiotic resistance or the negative effects on the health of the patients 
(Salas-Jara et al., 2016). In a recent study, it was shown that probiotics may reduce 
infection complications in the critically ill patients and may contribute to earlier 
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recovery of gut function, although mortality was not proved to be reduced (Koekkoek 
and van Zanten, 2017). Curiously, the gram-negative probiotic Escherichia coli (Nissle 
1917) was even more effective than gram-positive probiotics (Lactobacilli spp.) at 
enhancing protective immunity against rotavirus in the gnotobiotic piglet model 
(Kandasamy et al., 2017). 
 Focusing now on chronic digestive disorders, these may be divided into two main 
categories: organic and functional disorders. Organic disorders are those in which 
alterations of the gut wall structure are patent and clearly related to the disorder. In 
this category, all kinds of inflammatory-based alterations may be included: gastritis, 
gastric ulcer, gastric or colorectal cancer, inflammatory bowel disease (IBD), including 
ulcerative colitis and Crohn’s disease, microscopic colitis, celiac disease… In contrast, 
the term “functional”, used for functional GI diseases (FGID), including both functional 
dyspepsia and irritable bowel syndrome (IBS), indicates that structural or biochemical 
abnormalities that could explain the symptoms are not evident, based on routine 
clinical evaluations (Mearin et al., 2016; Tack and Drossman, 2017).  
Whereas in organic diseases pain may be present, probably as a consequence 
of the inflammatory condition itself, in FGID pain is present but its aetiology is not so 
clear: it may be related to motility alterations and/or to micro- or low-grade 
inflammation [i.e., mastocytosis, that could be treated with anti-histamine drugs: 
(Fabisiak et al., 2017)] that only recently is being considered [see for example  
(Holtmann et al., 2016) for a recent review on IBS pathophysiology]. First, we will 
provide some recent examples of studies about probiotics potential to treat three 
main organic disorders: gastric ulcer (and infection by H. pylori); IBD; GI cancer. 
Thereafter, we will illustrate the use of probiotics to treat FGID, and, particularly, pain 
associated to IBS. 
3.1. INFLAMMATORY CONDITIONS IN THE GASTROINTESTINAL TRACT   
3.1.1. Evidence from in vitro studies 
 Many recent in vitro studies have shown that probiotics may exert interesting 
activities leading to a reduced inflammation. For example, regarding H. pylori infection 
and consequent gastric inflammation, Streptococcus thermophilus CRL1190 strain 
reduced H. pylori adhesion and attenuated inflammatory response in AGS gastric 
epithelial cell line. Also, Lactobacillus paracasei strain 06TCa19 increased IL-8 and 
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RANTES expression in AGS and MKN45 cells, decreased NF-κβ, p38 MAPK signaling, 
lactic acid release and CagA virulence protein of H. pylori (Takeda et al., 2017). 
Similarly, the commensal Bacteroides fragilis was shown to enhance the phagocytic 
functions of macrophages, polarizing them to an M1 phenotype, which highlights the 
relationship between this bacterium and the innate immune system (Deng et al., 
2016). Probiotics are also known to dampen the Th1 response triggered by H. pylori, 
adherence to the gastric epithelium and secretion of bacterial adhesins and 
bacteriocidal metabolites (Boltin, 2016). 
3.1.2. Evidence from animal models  
 Different animal models have been used to test the role of different types of 
probiotics in vivo. For example, Lactobacillus fermentum Suo (LF-Suo) inhibited, in a 
dose-dependent manner, HCl/ethanol induced gastric injury in mice and the 
mechanisms involved improvements in mucosal barrier, antioxidant activities, 
reduction of serum cytokines (IL-6, IL-12, TNF-α, IFN-γ), increase in serum motilin, 
substantia P (SP), endothelin, somatostatin and vasoactive intestinal peptide (VIP), and 
the normalization of several gastric proteins gene expression (Suo et al., 2016). Also in 
mice models of gastric ulcers induced by alcohol, restraint cold stress and pyloric 
ligation, Clostridium butyricum exerted antioxidative and anti-inflammatory effects 
leading to significantly reduced gastric mucosal injury (Wang et al., 2015a). 
In the IBD field, one recent work has shown that iron-responsive Streptococcus 
thermophilus strain was able to ameliorate colitis induced by dextran sodium sulphate 
(DSS) in mice. This has been suggested as an alternative to conventional probiotics, 
which in the iron-rich environment of the colon of IBD patients (due to bleeding and 
oral iron supplements) would not be as effective. The mechanism involved 
maintenance of mucosal barrier function and reduced bacterial translocation, thereby 
reducing immune stimulation and associated inflammation, leading to mucosal 
healing, as well as to reduced GI bleeding and weight loss (Bailey et al., 2017). 
Interestingly, using the same model, the beneficial actions of Escherichia coli (Nissle 
1917) were potentiated when it was combined with iron supplementation in the form 
of ferrous sulphate (which is currently used in the clinics to supplement IBD patients), 
but not of other iron supplements (Constante et al., 2017). Also, in another recent 
report, Lactobacillus casei 01 was used alone and/or combined with oligofructose-
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enriched inulin in a trinitrobenzenesulfonic acid (TNBS)-induced rat model of colitis. 
This combination of the probiotic and the prebiotic (oligofructose-enriched inuline) 
was also tested after its encapsulation in chitosan-Ca-alginate microparticles, which 
showed the best anti-inflammatory effects (Ivanovska et al., 2017). Thus, even though 
in vitro studies show that probiotics on their own may exert beneficial effects in 
inflammatory conditions, a currently hot line of research in preclinical studies is to 
optimize their in vivo effects, mainly through the combination (after encapsulation or 
not) with other compounds (prebiotics, nutrients, nutraceuticals…).  
3.1.3. Evidence from clinical studies  
 In clinical studies, probiotics may have a significant protective effect in several 
inflammatory conditions of the gut, although evidences are not available for all 
conditions. For example, it has recently been shown that probiotics may decrease the 
incidence of acid-suppressing drugs-associated infections, especially in the elderly 
(Fisher and Fisher, 2017). In both children and adults, either Asians or not, a recent 
meta-analysis showed that the addition of probiotics improved H. pylori eradication 
rates, associated to immune system modulation, and, very interesting, probiotics 
improved medication tolerance and patient compliance with lower levels of nausea, 
vomiting, diarrhea and epigastric pain (Lau et al., 2016). In a recent review about 
treatment of gastric ulcer, it was concluded that some probiotics may increase the 
efficacy and tolerability of the triple therapy, although data related to quadruple 
concomitant therapy are not definite yet (Gisbert, 2016). Furthermore, it is not clear 
yet the specific probiotic/s, antibiotic/s and patient factors that might predict benefit 
from probiotic supplementation in the treatment of gastric ulcer and H. pylori infection 
(Boltin, 2016). 
Similarly, in the IBD field, a very recent meta-analysis considering a total of 22 
randomized clinical trials, showed that VSL#3, a mixture of 8 probiotic bacteria strains, 
may be effective in inducing remission in active ulcerative colitis, and that probiotics 
may be as effective as 5-aminosalicylates (5-ASAs) in preventing relapse of quiescent 
ulcerative colitis. However, the efficacy of probiotics in Crohn’s disease remains 
uncertain, and more evidence from randomized control trials is required (Derwa et al., 
2017). Similar results were obtained by another research group (Ganji-Arjenaki and 
Rafieian-Kopaei, 2017).  
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3.2. GASTROINTESTINAL CANCERS 
 Regarding GI neoplasias, several recent in vitro studies have shown that 
probiotics may exert anti-proliferative and pro-apoptotic effects on cancer cells, 
although the mechanism involved has not been completely elucidated (Haghshenas et 
al., 2014; Orlando et al., 2012). In in vitro studies using gastric cancer cell lines, 
Lactobacillus reuteri down regulated urokinase plasminogen activator/urokinase 
plasminogen activator receptor gene expression (Rasouli et al., 2017). Also in gastric 
cancer cell lines and xenograft models, ferrichrome (a siderophore) from Lactobacillus 
casei ATCC334 induced apoptosis (Ijiri et al., 2017). Lactobacillus salivarius Ren in rats 
and Clostridium butyricum and Bacillus subtilis in mice were capable of inhibiting 
dysbiosis and suppressing colon carcinogenesis (Chen et al., 2015; Zhang et al., 2015).  
 Probiotics may also improve small intestinal bacterial overgrowth, as shown in 
a Chinese cohort treated with Bifidobacterium triple viable capsule. In this study, small 
intestinal bacterial overgrowth was related to GI cancer (gastric and colorectal) and 
concomitant GI cancer-related symptoms, which were alleviated by the probiotic 
(Liang et al., 2016). In addition, probiotics can prevent the toxic effects (diarrhea) of 
chemotherapy and radiotherapy in cancer patients (Chitapanarux et al., 2010; 
Osterlund et al., 2007). Once again, restoration of normal microflora may play a key 
role in these effects. 
3.3. FUNCTIONAL GASTROINTESTINAL DISORDERS AND VISCERAL PAIN 
 Despite FGID are not categorized as organic diseases, and thus not 
considered as inflammatory conditions, some subtle (low-grade) inflammation has 
been observed in both IBS and FD (Camilleri et al., 2012; Holtmann et al., 2016; Lee et 
al., 2017; Ohman and Simrén, 2010). Actually, this subtle inflammation may participate 
in the development of symptoms, including pain. In some patients, FGID may have a 
genetic basis (Beyder et al., 2014; Oshima et al., 2010; Saito et al., 2009). However, 
other factors have been involved in the development of FGID such as early life events 
and stress, autoimmune disorders and atopy, infections, disordered mucosal immune 
activation, and the gut microbiome (Holtmann et al., 2016; Talley et al., 2015).  
Whether gut dysbiosis in IBS is a cause or a consequence of the disease remains 
unclear (Theodorou et al., 2014), but physiologic effects of altered microbiota include 
bile salt de-conjugation changes leading to changes in stool volume and consistency, as 
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well as bacterial fermentation changes resulting in alterations in the gas volume 
and/or composition, which may underlie the motility alterations typically encountered 
in this disease (Quigley, 2013, 2017). Motility alterations may facilitate the occurrence 
of pain. 
However, the intestinal microbiota secretes factors that may alter mucosal 
permeability, activate different types of immune cells and responses, and induce the 
release of cytokines. These alter visceral pain responses. Interestingly, visceral pain is 
reduced in germ free mice and is also reduced after administration of antibiotics for 2 
weeks in mice (Aguilera et al., 2015). Changes in secretory immunoglobulin A (IgA), 
toll-like receptors (TLR) as well as in cannabinoid and mu opioid receptors were shown 
to be involved in the effect of antibiotics (Aguilera et al., 2015). Thus, some of the 
effects of the microbiota on visceral pain responses are mediated via microbiota-
neuroimmune interactions. Changes in mucosal permeability, mucosal immune system 
composition and the microbiome populations have been described in humans with 
IBS, further suggesting that microbiota-neuroimmune interactions are key in some 
visceral pain syndromes (Hughes et al., 2013). Despite the lack of identification of a 
specific microbial group characteristic for IBS dysbiosis the alterations generally 
reported concern the Bifidobacterium and Clostridium coccoides-E. rectal subgroup.  
Importantly, in addition to gut dysbiosis, visceral pain and psychiatric co-
morbidity are common features in FGID, including IBS (Mayer, 2011). The origin of 
visceral hypersensitivity in IBS can be central and/or peripheral (Barbara et al., 2011). 
Thus, increased neuron excitability has been reported at several levels of the brain-gut 
axis, i.e., the ENS, spinal cord and supraspinal sites (Feng et al., 2012). At the supra-
spinal sites, interactions with emotional or stressful influences can modulate the 
visceral sensitivity resulting in increased pain perception (Hertig et al., 2007). These 
interactions will be discussed further in this review. 
Increased neuron excitability in IBS, in the absence of major inflammation, may 
be related to the underlying aetiology. For example, IBS may develop after an episode 
of gastroenteritis and symptoms may still be observed in 10% of patients up to 10 
years after the infectious event. Prospective studies have determined that 3-36% of 
enteric infections lead to persistent new IBS symptoms (Spiller and Garsed, 2009), and 
the following factors seem to be key for their occurrence: gender (female); severe 
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symptoms during the infection; infected by Salmonella (as opposed to Escherichia coli); 
and higher anxiety, depression and somatization baseline scores (Schwille-Kiuntke et 
al., 2011). Prior infection might trigger subtle local inflammation and persistent 
neuronal hypersensitization. 
On the other hand, during the early neonatal period, there is a critical window 
at which the microbial colonization of the GI tract influences the development of both 
the peripheral and central nervous system. Maternal separation, an established model 
of stressor exposure early in life, alters microbiome composition in monkeys and rats. 
This change has been shown to be associated with exaggerated visceral pain responses 
in the rat that persist in adulthood (Barouei et al., 2012). Thus, the early neonatal 
period is also critical for the development of the neural nociceptive pathways and 
sensory nerves. Stress experienced in early life triggers long-term changes in visceral 
sensitivity to noxious stimuli (visceral hypersensitivity).  
3.3.1. Evidence from animal models 
 Probiotics have been shown to balance altered microbiome in these 
syndromes, particularly in animal models. Some evidences will be provided next. 
Different evidences have shown that administration of probiotic bacteria modifies 
neuronal excitability and motility in animal models. Thus, administration of 
Lactobacillus species (L. rhamnosus, L. reuteri) increases enteric neuron excitability and 
modulates intestinal motility in rodents (Kunze et al., 2009; Wang et al., 2010a, 
2010b). Lactobacillus farciminis exerts antinociceptive effects by altering central 
sensitization (Ait-Belgnaoui et al., 2009).  
Lactobacillus spp. have been implicated in the modulation of visceral pain. For 
example, excitability of dorsal root ganglia in response to colorectal distension is 
prevented by L. rhamnosus treatment (Ma et al., 2009), and, in another study, 
treatment with Lactobacillus species up regulated mu-opioid and cannabinoid 
receptors expression in rats and mice, leading to visceral analgesia (Rousseaux et al., 
2007). Also, the efficacy of 3 different probiotics (Lactobacillus salivarius UCC118, B. 
infantis 35624, and Bifidobacterium breve UCC2003) on the abdominal response to 
colorectal distension was compared using visceral normosensitive rats (Sprague-
Dawley) and visceral hypersensitive rats (Wistar Kyoto), and only B. infantis 35624 was 
able to reduce the colorectal distension-induced pain behavior in both rat strains 
Roman et al.  Probiotics in digestive, emotional and pain-related disorders 
 13 
(McKernan et al., 2010), suggesting that strain specificity might be a key factor to 
consider when using probiotics to treat/avoid visceral pain. 
In the rat, instillation of zymosan into the colon during the neonatal period 
produced short-term inflammation and subsequent long-term colonic hypersensitivity. 
Chronic visceral hypersensitivity occurring in adulthood in these animals was 
attenuated by L. rhamnosus ATCC 53103 (Lactobacillus GG; LGG) and, to a lesser 
extent, by a prebiotic mix (galactooligosaccharides and polydextrose) (Kannampalli et 
al., 2014). Furthermore, LGG was found to alter the levels of brain neurotransmitters, 
like serotonin, noradrenaline, and dopamine, all involved in pain modulation (Marks et 
al., 2009). Treatment with live and killed L. reuteri prevented the pain response to 
colorectal distension by decreasing distension-induced electrophysiological neuronal 
activity in the dorsal root ganglion (Kamiya et al., 2006). A decrease of normal visceral 
perception and chronic colonic hypersensitivity, elicited by butyrate was also observed 
after oral treatment with L. acidophilus NCFM (Rousseaux et al., 2007). 
Acute and chronic stress models are widely used as IBS-like models, since stress 
induces gut hyper-permeability and visceral hypersensitivity in response to colorectal 
distension (Theodorou et al., 2014). For example, chronic fatigue was induced in rats 
by forcing them to swim in water till exhaustion (prolonged forced swim test). In this 
test, oral administration of Lactobacillus acidophilus significantly decreased immobility 
and post-swim fatigue time and attenuated oxido-nitrosative stress and TNF-α levels 
(Singh et al., 2012). Additionally, in two stress models in rats (acute restraint stress and 
neonatal maternal deprivation), 3 probiotic strains were evaluated: Bifidobacterium 
lactis (NCC362), Lactobacillus johnsonii (NCC533), and Lactobacillus paracasei 
(NCC2461) (Lpa). Only treatment with Lpa significantly improved stress-induced 
visceral pain and restored normal gut permeability, further highlighting that particular 
live bacteria strains and their metabolites generated in the medium may be required 
to improve stress-induced IBS-like symptoms (Eutamene et al., 2007).  
A recent work by Darbarky (Darbaky et al., 2017) showed that treatment with 
two probiotics derived from the probiotic bacterial strain Lactobacillus rhamnosus may 
attenuate peripherally and centrally induced visceral hypersensitivity in rats, and it was 
suggested that it may be active in the treatment of IBS symptoms.  
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Finally, in the IBS rat model of neonatal maternal separation, early life 
administration of VSL#3 reduced visceral pain perception and reset colonic expression 
of subsets of genes mediating pain and inflammation (Distrutti et al., 2013), suggesting 
that changing the neurochemical milieu during the painful experience can modify the 
changes in visceral pain responses induced during infancy. 
3.3.2. Evidence from clinical studies  
There are some systematic reviews and meta-analysis that have explored the 
probiotic effects on abdominal or visceral pain in IBS. In general, results show a 
significant reduction of pain in both adults and children population after probiotics 
treatment (Didari et al., 2015).  
A recent review has found moderate- to low-quality evidence suggesting that 
probiotics may be effective in improving pain in children with recurrent abdominal 
pain (Newlove-Delgado et al., 2017). In the same population (paediatric 
abdominal pain-related FGID), L. rhamnosus (GG and VSL#3) were associated with 
significantly more responders to treatment (Rutten et al., 2015). 
In a clinical trial, comparing an 8-week treatment with B. infantis (35624) and L. 
salivarius (UCC118) in IBS patients, only B. infantis (35624) treated patients 
experienced a reduction in individual scores for abdominal pain and discomfort, 
bloating and distension (O’Mahony et al., 2005). However, also related to adults with 
IBS, a recent meta-analysis showed that treatment with B. infantis 35624 did not 
impact on abdominal pain, whereas patients who received a mixture of probiotics 
containing B. infantis had significantly reduced abdominal pain, suggesting that B. 
infantis (35624) combined with other probiotic strains could be more effective to 
manage pain in IBS patients (Yuan et al., 2017).  
Another effective probiotic strain capable of managing abdominal pain in IBS 
patients is S. cerevisiae (CNCM I-3856). This strain significantly improved the 
symptoms, with a 12.3% reduction of abdominal pain (Cayzeele-Decherf et al., 2017). 
Therefore, according to all the evidences cited above, probiotics seem to be 
effective treatments for pain management in IBS. However, which individual species 
and strains are most beneficial remains unclear (Ford et al., 2014).  
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4. EVALUATION OF PROBIOTICS IN PAIN DISORDERS  
Until now, a relatively limited number of studies has investigated the influence of gut 
microbiota on pain and nociceptive processes (Rea et al., 2017). Indeed, most of the 
research has focused on IBS, one of the FGID with more evidence for the effectiveness 
of probiotics administration (Didari et al., 2015; Tiequn et al., 2015). As previously 
mentioned, evidence for the use of prebiotics in IBS come from from animal studies 
and are mainly based on their ability (i) to modulate visceral sensitivity and (ii) to 
enhance intestinal barrier function and immunity (Theodorou et al., 2014).  
 Although preclinical studies have focused on IBS models, clinical studies 
have also addressed the role of probiotics in chronic fatigue syndrome and other 
conditions. Indeed, there is some evidence for the effectiveness of probiotics in 
Chronic Fatigue Syndrome. In an exploratory study, Sullivan and colleagues (Sullivan et 
al., 2009) evaluated the effect of L. paracasei ssp. Paracasei F19, L. acidophilus NCFB 
1748 and B. lactis Bb12 on fatigue and physical activity in 15 patients diagnosed with 
Chronic Fatigue Syndrome. Participants improved their neurocognitive functions, 
although no significant changes were reported either in fatigue or in the other 
variables measured, related to health and physical activity (Sullivan et al., 2009). Rao 
and colleagues (2009) found that patients with Chronic Fatigue Syndrome, treated for 
two months with Lactobacillus casei strain Shirota (LcS), showed a significant 
improvement in anxiety as compared with placebo (Rao et al., 2009). Groeger and 
colleages (2013) assessed the impact of the oral administration of B. infantis (35624), 
for 6‒8 weeks, in patients with Chronic Fatigue Syndrome; inflammatory biomarkers 
and plasma cytokine levels were evaluated, but not only, and results showed that the 
probiotic treatment reduced plasma levels of C-reactive protein, IL-6 and TNF-α in 
Chronic Fatigue Syndrome (Groeger et al., 2013). 
 Probiotics have also revealed their efficacy in the management of rheumatoid 
arthritis. The combination of the probiotic, Bacillus coagulans (GBI-30, 6086) with the 
standard anti-arthritic medication, for 60 days, notably enhanced analgesia, as 
evidenced by an improvement in the Pain Scale as well as in the Patient Pain 
Assessment score. In addition, a greater improvement in patient global assessment 
and self-assessed disability was also assessed after the probiotic administration 
(Mandel et al., 2010). An additional study showed that the administration of 
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Lactobacillus casei (01), for 8 weeks, to patients diagnosed with rheumatoid arthritis, 
induced a decrease in the disease activity score and significantly improved the 
inflammatory status of these patients. Probiotics seemed to decrease pro-
inflammatory cytokines: tumor necrosis factor-alpha (TNFα), IL-6, and IL-12, although 
no changes were observed in IL-1β levels (Vaghef-Mehrabany et al., 2014). Therefore, 
probiotics may emerge as a potential adjunctive therapy for rheumatoid arthritis 
patients.  
 Despite a theoretical rationale for a probiotic therapy in other pathologies such 
as spondyloarthritis, no benefits have been demonstrated in clinical trials. The 
combination of probiotics, Streptococcus salivarius (K12), Bifidobacterium lactis (LAFTI 
B94), and Lactobacillus acidophilus (LAFTI L10), for 12 weeks, did not achieve any 
difference over placebo in any of the core domains analysed: Bath Ankylosing 
Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional 
Index (BASFI), Maastricht Ankylosing Spondylitis Enthesitis Score (MASES). Thus, in this 
randomized controlled trial, the probiotic combination administered did not 
demonstrate significant benefit over placebo (Jenks et al., 2010).  
 
5. APPLICATION OF PROBIOTICS IN EMOTIONAL DISORDERS  
As already described, microbiota plays an essential role in GI diseases (Martin and 
Kochhar, 2015), and, surprisingly, its seems also to be critically related to brain 
physiology and behaviour, thus possibly affecting mental health (Borre et al., 2014; 
Carabotti et al., 2015; Cryan and Dinan, 2012; Dinan et al., 2014). Actually, probiotics 
have emerged as a potential intervention to manage anxiety and depression, at least, 
in animal models. Indeed, the term psychobiotics was coined to describe the beneficial 
effects of probiotics in patients suffering from psychiatric illnesses (Dinan et al., 2013). 
5.1. Evidence from preclinical models 
Preclinical studies have focused on anxiety and depression (Huang et al., 2016). 
The administration of probiotics consistently induces anxiolytic- and anti-depressive-
like responses in rodents. The chronic administration of Lactobacillus rhamnosus (JB-1) 
enhanced the exploration of the open-arms of an elevated plus-maze, indicative of an 
anxiolytic-like effect, although animals did not change their behavior in the stress-
induced hyperthermia test. Moreover, the stress-induced corticosterone response was 
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significantly attenuated by the administration of this probiotic (Bravo et al., 2011). 
Similar results have been reported in rats, tested in the elevated plus maze, following 
the administration of Lactobacillus fermentum (strain NS9) (Wang et al., 2015), in 
mice, evaluated in the Barnes test, after Lactobacillus helveticus (ROO52) 
administration (Ohland et al., 2013), as well as in germ-free mice administered with 
Lactobacillus plantarum (PS128) and evaluated in the elevated plus-maze (Liu et al., 
2016a).  
More importantly, probiotics also act as effective anxiolytics in animal models 
with an anxious phenotype. Animals exposed to a protocol of early life stress, maternal 
separation (3 h/day from days 4 to 19), present an altered activity of the 
hypothalamus-pituitary-adrenal (HPA) axis demonstrating increased basal serum 
corticosterone levels; the administration of a mixture of two strains of Lactobacillus 
species was able to revert the enhanced level of circulating corticosterone (Gareau et 
al., 2007). In mice, Lactobacillus helveticus (ROO52) successfully prevented the 
negative effects of a Western-style diet on anxiety (Ohland et al., 2013). 
Immunodeficient mice, B and T cell-deficient Rag1(-/-) mice, exhibit increased anxiety 
levels, in the light-dark box, as well as augmented levels of circulating corticosterone; 
the administration of a mixture of Lactobacillus was able to prevent the former 
without affecting the HPA axis activity (Smith et al., 2014). However, some negative 
data have also been reported, e.g. the administration of Lactobacillus 
rhamnosus (NCC4007) was not effective in the management of the anxious state 
reported in an animal model of low-grade colitis (Bercik et al., 2010), although, in this 
case, the administration of another probiotic, Bifidobacterium longum (NCC3001), 
successfully reverted the anxiety-like behavior associated to chronic colitis (Bercik et 
al., 2010, 2011). The combination of Lactobacillus Helveticus (R0052) and 
Bifidobacterium longum (R0175) has also been investigated, and promising anxiolytic-
like effects were reported in rats by using the conditioned defensive burying test of 
anxiety (Messaoudi et al., 2011). More recently, the administration of Lactobacillus 
rhamnosus (JB-1) was able to prevent the stress-induced anxiety-like behavior 
observed in mice chronically exposed to social defeat. In the study, L. rhamnosus (JB-
1)  successfully prevented the deficits in social interaction with conspecifics although 
this probiotic was not able to counteract the avoidance to the aggressor, thus 
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indicating a possible dissociation between several forms of anxiety-like behavior 
(Bharwani et al., 2017).  
The vagus nerve seems to play a pivotal role in the anxiety-like effects of 
probiotics. The anxiolytic-like effects of L. rhamnosus (JB-1) were not found in 
vagotomized mice (Bravo et al., 2011). Moreover, in the chronic colitis animal model, 
anxiety-like behavior is vagally mediated, and the anxiolytic effect of B. longum 
required vagal integrity (Bercik et al., 2011). Bacteria may alter the excitability of 
enteric neurons, which may signal to the central nervous system by activating vagal 
pathways at the level of the ENS. Some other neuroactive substances released by gut 
bacteria, such as serotonin, noradrenaline, and dopamine, may also be involved in the 
emotional effects of probiotics. Potential mechanisms underlying the emotional 
actions of probiotics will be discussed in the next section. 
Regarding antidepressant-like effects, controversial data have been reported. 
The chronic administration of Lactobacillus rhamnosus (JB-1) significantly reduced the 
time animals spent immobile in the forced swim test (FST) (Bravo et al., 2011) whereas 
Lactobacillus plantarum (PS128) administered to germ-free (GF) mice did not affect 
depression-like behaviors in the FST (Liu et al., 2016a). However, results become 
consistent if probiotics are tested in “depressed” animals. Bifidobacterium infantis 
(35624) effectively reversed the depressive phenotype of animals submitted to the 
maternal separation protocol (Desbonnet et al., 2010), and L. helveticus (NS8) 
demonstrated its antidepressant properties in the chronic restraint stress model of 
depression (Liang et al., 2015); in these two studies probiotics had similar effects than 
the usually prescribed antidepressant citalopram (Desbonnet et al., 2010; Liang et al., 
2015). In addition, the combination of probiotics (L. helveticus and B. longum) was 
effective in the prevention of depressive-like symptoms associated to an animal model 
of myocardial infarction, in particular, this combination reversed the behavioral 
despair, the abnormal social interaction levels as well as the impaired processing of 
emotional memory reported following the surgical intervention (Arseneault-Bréard et 
al., 2012). 
It is worth mentioning that probiotics have shown a positive impact in cognitive 
function. Recent studies have reported that mice fed with L. rhamnosus (JB-1) 
displayed an enhanced memory towards cues and context (Bravo et al., 2011); and 
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mice fed with B. longum (1714) performed better in the object recognition test 
(discriminating faster between the two objects than other groups), in the Barnes maze 
(performing less errors than other groups) as well as in the fear conditioning test 
(Savignac et al., 2015). Notably, probiotics do not only seem to improve cognition per 
se but they are also able to counteract the memory impairments reported in several 
animal models. As an example, Lactobacillus fermentum (strain NS9) alleviated the 
ampicillin-induced impairment in memory retention evaluated in the Morris water 
maze (Wang et al., 2015); and Lactobacillus helveticus (ROO52) prevented the memory 
impairment associated to a Western-style diet (Ohland et al., 2013). 
Insert Table 1 around here 
  
Finally, results from animal models give further support to the potential anxiolytic 
and anti-depressant properties of probiotics. Recent studies have also proposed 
probiotics, in particular Lactobacillus rhamnosus (GG), as a valid strategy for the 
treatment of obsessive-compulsive disorder (OCD) since it effectively normalized the 
hyperlocomotion, stereotypes and perseverative behavior observed in an animal 
model of this disorder (Kantak et al., 2014). Probiotics have opened new avenues in 
the management of emotional disorders, however little is known yet regarding the 
underlying mechanisms. 
5.2. Evidence from human studies 
The reported anxiolytic and anti-depressant properties of probiotics may be 
effectively translated into the human population, although further studies and clinical 
trials are still needed.  
One of the first studies, by Benton and colleagues (2007), was a double-blind 
placebo-controlled trial in which a yogurt containing L. Casei Shirota, or a placebo, was 
administered for 3 weeks. Despite the probiotic did not generally change the mood, a 
trend for improving the mood in those that were more depressed was reported. In line 
with this observation, Lactobacillus casei strain Shirota (LcS) administered daily for two 
months to a population suffering from Chronic Fatigue Syndrome provoked a decrease 
in anxiety symptoms evaluated by using the Beck Depression and Anxiety Inventories 
(Rao et al., 2009). The combination of Lactobacillus Helveticus (R0052) and 
Bifidobacterium longum (R0175) seems also to be useful as an anti-stress/anti-anxiety 
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agent in healthy volunteers (Messaoudi et al., 2011). In the same line, a recent 
research show that B. longum 1714 strain alone can ameliorate both the physiological 
and psychological response to an acute stressor, as well as longer-term daily self-
reported psychological stress, in healthy human adults. In addition, in the group 
treated with the probiotic a subtle improvement in visuospatial memory performance, 
as well as an EEG profile consistent with improved memory was observed (Allen et al., 
2016). However, in a more recent study, Lactobacillus rhamnosus (JB-1) was not 
superior to placebo in modifying stress-related measures in healthy male participants 
evaluated during and after a socially evaluated cold pressor test (SECPT) (Kelly et al., 
2017). 
In parallel with the findings in preclinical studies, in humans, the administration 
of probiotics arises as a more powerful tool when treating altered emotional states. 
Probiotics effectively ameliorated anxiety symptoms in laryngeal cancer patients 
before surgery (Yang et al., 2016). Also, Lactobacillus rhamnosus HN001 (HN001) 
reduced the levels of depression and anxiety scores in the postpartum period 
(Slykerman et al., 2017). Probiotics administration, Lactobacillus casei strain Shirota 
(LcS), exerted beneficial effects preventing the onset of physical, physiological, and 
psychological symptoms reported in healthy subjects exposed to a stressful situation, 
an authorized nationwide examination for promotion (Kato-Kataoka et al., 2016). 
Authors propose that both the HPA axis and the serotonin system could be affected by 
probiotics, and may thus account, at least partially, to their anxiolytic-like actions 
(Kato-Kataoka et al., 2016). 
Food supplementation with a multispecies probiotic has been proposed as a 
strategy to reduce negative thoughts associated with sad mood, and thus it might be 
used as a potential preventive strategy for depression (Steenbergen et al., 2015). 
Indeed, an altered microbiota composition has been reported in patients diagnosed 
with major depressive disorder (MDD) (Jiang et al., 2015). More recently, the 
antidepressant properties of probiotics have been confirmed in a depressed 
population. A clinical study has been performed analyzing the effects of probiotic 
intake in patients with MDD; the probiotic administration effectively decreased the 
depressive score of these patients (Akkasheh et al., 2016). Actually, probiotics, in a 
yogurt or in a multispecies probiotic capsule, have induced significant improvements 
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both in a General health questionnaire (GHQ) as well as in the Depression anxiety and 
stress scale (DASS) in petrochemical workers (Mohammadi et al., 2016).  
 
Insert Table 2 around here 
 
Moreover, the brain response to probiotics has also been investigated by 
functional Magnetic Resonance Imaging (fMRI). Pinto-Sanchez and co-workers (2017) 
evaluate in a prospective study the effects of Bifidobacterium longum NCC3001 (BL) on 
anxiety and depression in patients with IBS. They found that BL reduces depression but 
not anxiety scores and increases quality of life. In addition, the fMRI analysis showed 
that BL reduced responses to negative emotional stimuli in multiple brain areas as 
amygdala. In other study, a small population of healthy women was exposed to a 
probiotic, containing Bifidobacterium animalis subsp Lactis, Streptococcus 
thermophiles, Lactobacillus bulgaricus, and Lactococcus lactis subsp Lactis, and then 
tested in the fMRI by using an emotional faces attention task and resting brain activity. 
The study revealed that this probiotic affected activity of brain regions that control 
central processing of emotion and sensation (Tillisch et al., 2013). In a more recent 
research in healthy women Tillisch and co-workers (2017) identified two clusters of 
subjects defined by the genera Bacteroides and Prevotella. The Prevotella group 
showed less hippocampal activity viewing negative valences images and was 
associated with differences in emotional, attentional, and sensory processing regions. 
For gray matter, the Bacteroides cluster showed greater prominence in the 
cerebellum, frontal regions, and the hippocampus. However, if the microbiota brain 
connections showed reflect the modulation of the gut microbiota structure the brain, 
or the influence of the microbiota on the brain and its affective responses, is still 
unknown. 
 
6. PUTATIVE MECHANISMS UNDERLYING THE CENTRAL EFFECTS OF PROBIOTICS  
Probiotics, as previously exposed, play a relevant role in the management of GI, 
emotional and pain-related disorders. Many mechanisms have been shown to be 
involved in this bidirectional pathway between the microbiota and the brain. 
Communication through the neural pathway is mainly mediated through the vagus 
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nerve and the ENS. The HPA axis - via glucocorticoids - as well as the immunological 
pathway - through the modulation of cytokines - seem to be essential in this 
communication. More recently, microbiota has been proposed as an epigenetic entity 
(Stilling et al., 2014). However, the mechanisms involved in their effects are still under 
discussion [see (Carabotti et al., 2015; Cryan and Dinan, 2012; El Aidy et al., 2016; Wall 
et al., 2014) for an updated review of the topic].  
Probiotics may alter emotionality and pain perception by acting on the central 
nervous system. Increased neuron excitability has been reported at several levels of 
the brain-gut axis, i.e., ENS, spinal cord and supraspinal sites (Feng et al., 2012). At the 
supra-spinal sites, interactions with emotional or stressful influences can modulate the 
visceral sensitivity resulting in increased pain perception (Hertig et al., 2007).  
The vagus nerve has emerged as a crucial factor in the emotional effects of 
probiotics. As previously reported the anxiolytic-like effects of L. rhamnosus (JB-1) 
were not found in vagotomized mice (Bravo et al., 2011), and B. longum required vagal 
integrity to exert its anxiolytic effects in an animal model of colitis-induced anxiety 
(Bercik et al., 2011). B. longum metabolites decreased excitability of enteric neurons 
(Bercik et al., 2011) which may in turn signal to the central nervous system by 
activating vagal pathways at the level of the ENS. The anxiolytic actions of probiotics 
may be vagally mediated, however, as much as we are concerned, the involvement of 
vagal nerve in the analgesic effects of probiotics has not yet been investigated. 
Gut microbiota produce several microbial metabolites such as short chain fatty 
acids, vitamins and chemotactic peptides (Bercik and Collins, 2014; De Palma et al., 
2014; Sherwin et al., 2016) that can bind to receptors expressed on enteroendocrine 
cells to facilitate secretion of a variety of peptides that can act locally on nearby 
intestinal epithelium and immune cells, can activate neurons of the ENS, and can also 
act in remote sites such as the brain (Furness et al., 2013).  
Increasing data give support to microbially produced molecules with 
neuroactive functions such as γ-aminobutyric acid (GABA), serotonin, catecholamines 
and acetylcholine which can modulate neural signalling within the enteric nervous 
system, when released in the intestinal lumen, and consequently interfere with brain 
function and behaviour (Patterson et al., 2014). Actually, many of these 
neurotransmitters have been isolated from bacteria within the human gut (Wall et al., 
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2014). Chronic live PS128 ingestion significantly increased the levels of both serotonin 
and dopamine in the striatum, but not in the prefrontal cortex or hippocampus (Liu et 
al., 2016a). The administration of Bifidobacterium infantis was able to restore basal NA 
concentrations in the brainstem of animals exposed to early maternal separation 
(Desbonnet et al., 2010). L. helveticus (NS8) restored hippocampal serotonin and 
norepinephrine levels in an animal model of depression, the chronic stress in rats 
(Liang et al., 2015). In humans, some species of Lactobacillus have been reported to 
prevent the increase in plasma L-tryptophan, a precursor of serotonin, detected before 
the exposure to a certain stress, and was able to increase the concentration of fecal 
serotonin in the long term (Kato-Kataoka et al., 2016). Region-dependent alterations in 
GABAA and GABAB receptor expression have been described following chronic 
treatment with L. rhamnosus (JB-1). The probiotic induced an increase in GABAB in 
cortical regions (cingulate and prelimbic) and concomitant reductions in the 
hippocampus, amygdala, and locus coeruleus; while GABAA exhibited a reduction in the 
prefrontal cortex and amygdala, but an increase in the hippocampus (Bravo et al., 
2011). 
Neurotrophins, and more specifically Brain Derived Neurotrophic Factor 
(BDNF), has been given a central role in the pathophysiology of depression. The 
administration of B longum restored the diminished hippocampal BDNF levels 
observed in an animal model of low-grade colitis (Bercik et al., 2010). Actually, the 
administration of L. helveticus (NS8) increased hippocampal BDNF mRNA expression, 
thus suggesting a common mechanism of action between probiotics and actual 
antidepressants (Liang et al., 2015). However, discrepant results in which no changes 
in BDNF levels were observed have also been reported for B. longum (Bercik et al., 
2011).  
The HPA axis might also been involved in the microbiota-brain interaction. 
Despite inconsistencies, probiotics have been reported to affect the HPA activation. L. 
helveticus (NS8) resulted in lower plasma corticosterone (CORT) and 
adrenocorticotropic hormone (ACTH) levels (Liang et al., 2015); and Bifidobacterium 
infantis restored the MS-induced changes in amygdala corticotrophin-releasing factor 
(CRF) mRNA levels (Desbonnet et al., 2010). These changes in the HPA activation might 
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play a critical role in the emotional actions of probiotics, although the connection 
pathway between microbiota and the HPA axis deserves further investigation. 
Probiotics may also alter emotionality and pain perception by acting via 
microbiota-immune interactions. Cytokines produced in the GI tract might be able to 
cross the blood-brain barrier, affecting the central nervous system, and thus possibly 
modulating mood and behavior. L. helveticus (NS8) resulted in higher plasma IL-10 
levels (Liang et al., 2015), whereas Bifidobacterium infantis , normalized the enhanced 
peripheral IL-6 release reported in the maternal separation animal model (Desbonnet 
et al., 2010). 
Pain relief actions of probiotics have been related with the opioid and the 
cannabinoid system. Treatment with Lactobacillus species in an animal model of IBD 
up-regulated colonic mu-opioid receptor (MOR) and cannabinoid receptor 2 (CB2R) 
expression in rats, together with a reduction in visceral sensitivity (Rousseaux et al., 
2007). In humans with mild to moderate abdominal pain, the probiotic Lactobacillus 
acidophilus (NCFM) induced an increase in colonic MOR expression, as well as 
downstream signaling as measured by enterocyte STAT3-phosphorylation. In contrast, 
CB2R expression was decreased (Ringel-Kulka et al., 2014). Although the opioid system 
emerges as a plausible mechanism of action by which probiotics modulates pain 
sensation in humans, research on the role played by the endocannabinoid system 
deserves further investigation. More recently, feeding rats with Lactobacillus reuteri 
(DSM 17938) inhibited perception of painful gastric distension and the vanilloid 
receptor TRPV1 has emerged as a specific target channel for a probiotic with potential 
therapeutic properties (Perez-Burgos et al., 2015). 
 
Esto es lo que nos dice  que metamos el segundo referee..yo la verdad, no lo 
veo…como no sea aquí en las conclusiones, no veo donde encaja 
“Due to studies in humans can only assign correlations and not causality, a new 
model in which a human fecal microbiota is established in germ-free mice through 
microbiota transplantation (HMA) has been employed. However, there is some limitations 
of this models that need to be elucidated. For example, whether the donor human 
microbiota was successfully transplanted into the mice and whether the human dysbiosis 
patterns were reproduced is still unknown (Arrieta et al., 2016).” 
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Dietary supplementation with probiotics and prebiotics are the most widely 
used dietary adjuncts to modulate the gut microbiota. Furthermore, evidence is 
emerging of the interactions between administered microbes and dietary substrates, 
leading to the production of pharmabiotics, which may directly or indirectly positively 
influence human health (Patterson et al., 2014). 
CHALLENGES: In choosing a probiotic strategy, clinicians should adhere to the 
principles of evidence-based therapeutics. These include: selection from a reputable 
supplier, with appropriate documentation of contents and shelf life; anticipation of 
strain-specific effects; avoidance of cocktails without documentation of the activities 
of each ingredient with absence of interstrain antagonism; and published evidence of 
efficacy from clinical trials (Shanahan and Collins, 2010). 
 
The translational study carry out with Kelly and co-workers (2017) (Kelly et al., 
2017) in healthy volunteers they failed to replicate their preclinical findings. These 
research highlights the challenges in translating the findings from candidate 
psychobiotics in stresssusceptible animals, to healthy human populations. One of 
these challenges in translation from animals to humans requiere a cultural change for 
the food and probiotic industry to carry out the level of investment required for such 
clinical trials to prove efficacy (Dinan and Cryan, 2016). 
Therefore, translation into human clinical investigations and the results of 
large-scale placebo-controlled trials are still awaited. Further investigation is needed to 




7. CONCLUSIONS AND FUTURE PERSPECTIVES 
Probiotics appear to be a safe strategy in the management of several GI, emotional 
and pain disorders. Most evidences come from animal models, but the translation 
from animal studies to the clinics still deserves further investigation. The design and 
performance of larger trials is urgently needed to verify whether these new strategies 
might be useful not only for the treatment of disorders affecting the GI tract but, 
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importantly, also emotional and pain disorders not directly related to the GI tract. In 
this regard, we have recently described a protocol for the evaluation of the efficacy of 
probiotics in fibromyalgia (Roman et al., 2017). The future application of probiotics in 
the clinic should take into consideration important aspects. The clinical desired effects 
may be specific of a particular specie of bacteria. To optimize the effects of probiotic 
specific combinations of bacteria might be of special interest, although the 
combination with other nutrients and/or nutraceuticals, or even the design of the 
vehicles may play a critical role in their effects (Nguyen et al., 2016). Last but not least, 
a better understanding of the mechanisms involved may open new avenues in the 
design of therapeutics that could enhance the clinical benefits pursued. 
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Tables 
TABLE 1. Effects of probiotic administration on emotional disorders: Evidence from animal models.  
Reference Animal model Probiotic administration Test Main findings 
Lactobacillus 
(Gareau et al., 2007) Sprague–
Dawley rats 
 
Mixture Lactobacillus:  
L. Rhamnosus (R0011, 
95%); L. Helveticus (R0052, 
5%) 
16 days 




Animal model: Neonatal maternal separation (MS) 
 The augmented basal corticosterone 
levels observed in MS animals were 
normalized. 
(Bravo et al., 2011) Mice 
Balb-c 
L. Rhamnosus (JB-1) 
Chronic 
28 days 
SIH No effects 
   EPM Increased open-arm entries 
   OF Increased time in the central  
   FST Decrease immobility time 
(Ohland et al., 2013) 129/SvEv mice L. Helveticus (R0052) 
21 days 
Barnes test Anxiolytic-like response 
(Smith et al., 2014) C57BL/6 mice  Mixture Lactobacillus: L. 
rhamnosus (R0011); L. 





Increased exploration of the light 
compartment in basal conditions and 
following psychological stress.  
Animal model: Immunodeficiency (Rag 1-/-)  
*No effects of probiotics were evaluated in wild type mice. 
HPA No changes in corticosterone levels. 
(Wang et al., 2015b) Rats L. Fermentum (NS9) 
30 days 
 
EPM Anxiolytic-like response 
(Liu et al., 2016b) Germ-free 
C57BL/6JNarl 
mice 
L. Plantarum (PS128) 
Chronic 
16 days 
OFT Increased locomotor activity 
Did not affect time spent in the 
central area. 
  EPM Increased the ratio of time spent in 
the open arm compared with time 
spent in the closed arm. 
   FST No changes in immobility time 
   HPA No changes in corticosterone levels. 
(Bercik et al., 2010) AKR mice L. rhamnosus (NCC4007) 
10 days 
LD Did not affect behaviour. 
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Animal model of low-grade colitis.  
*No effects of probiotics were evaluated in normal animals.  
SD Did not affect behavior. 
(Liang et al., 2015) Sprague-Dawley 
rats, specific 
pathogen free 
L. Helveticus (NS8) 
26 days 
SPT Reverted the anhedonia observed. 
  EPM Reverted the anxiety-like responses 
observed. 
   OF Improved behavior. 
   HPA Lower plasma corticosterone and 
adrenocorticotropic hormone (ACTH) 
levels. 
   ORT Counteracted cognitive deficits. 
Animal model: Chronic Restraint Stress depression model. OPT Improved cognition. 
(Bharwani et al., 
2017) 
C57BL/6 mice L. rhamnosus (JB-1)  
28 days 
 
OF Attenuated the observed deficit in 
rearing, exploratory activity.  
   LD Visited the light compartment more 
frequently, anxiolytic-like effect. 
   Social 
Preference 
Showed no preference between the 
social-no social chambers.  




Continued to exhibit a marked 
avoidance to their aggressor. 
Bifidobacterium 
(Bercik et al., 2010) AKR mice B. longum (NCC3001)  
10 days 
LD Reversed the anxious state observed.  
Animal model of low-grade colitis: parasite infection. 
*No effects of probiotics were evaluated in normal animals. 
SD Reversed the anxious state observed. 
(Bercik et al., 2011) AKR mice 
 
B. longum (NCC3001)  
1 week 
 
SD Normalized anxiety-like behaviour 
Animal model of chronic colitis: low dose dextran sodium 
sulfate (DSS) administration.  
*No effects of probiotics were evaluated in normal animals. 
  
(Desbonnet et al., 
2010) 
Rats  B. infantis (35624) 
45 days 
FST Reversed the depressive-like 
behaviours observed in MS animals  
Animal model: Neonatal maternal separation (MS)   
(Savignac et al., 
2014) 
BALB/c mice B. Longum (1724); B. Breve 
(1205). 
6 weeks 
ORT Discriminated faster between objects.  
   Barnes maze Performed fewer errors. 
   Fear 
conditioning 
Better learning and memory. 
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Combination: Lactobacillus & Bifidobacterium 




L. helveticus (R0052); B. 
Longum (R0175). 
2 weeks 
CDB Lower stress/anxiety score; effects 
similar to diazepam.  
(Arseneault-Bréard 
et al., 2012) 
Sprague–
Dawley rats 
L. helveticus (R0052); B. 
Longum (R0175). 
7 days + 11 days 
SI Returned social interaction to sham 
levels. 
 FST Normalized the MI-induced behavioral 
despair. 
Animal model of myocardial infarction (MI) SD Blighted processing of emotional 
memory. 
Abbreviations: HPA, HPA axis activity; SIH, Stress-induced hyperthermia; OF, Open field test; EPM, Elevated Plus-Maze; FST, 
Forced Swim Test; LD, Light-Dark Box; SD, step-down test; SPT, sucrose preference test; ORT, object recognition test; OPT, 
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TABLE 2. Effects of probiotic administration on emotional disorders: Evidence from human studies.  
Reference Population Probiotic administration Measurement Main findings 
Lactobacillus 
(Benton et al., 2007) General 
population 
(132 persons) 
L. Casei Shirota 
3 months 
Mood and Cognition The probiotic did not generally 
change the mood. 
However, a trend for 
improved mood in those that 
were more depressed was 
observed. 
An unexpected and possibly 
chance finding was that the 
consumption of probiotics 
resulted in a slightly poorer 
performance on two measures 
of memory. 




L. casei strain Shirota 
(LcS) 
2 months 
Beck Depression and 
Anxiety Inventories 
A decrease in anxiety 
symptoms. 





Lactobacillus casei strain 
Shirota (LcS) 
8 weeks 
Psychophysical state Lower reports of abdominal 
and cold symptoms. 
 Salivary cortisol The elevation observed before 
the examination in the 
placebo group was not 
evidenced.  
   Plasma L-tryptophan The elevation observed before 
the examination in the 




Faecal serotonin Increased two weeks after the 
examination. 
Subjects were exposed to stress, i.e. an authorized nationwide examination for promotion. 
(Slykerman et al., 
2017) 
Women recruited 





From enrollment up 





Women who received HN001 
had significantly lower 
depression in the postpartum 
period. 
   State Trait Anxiety 
Inventory 6 item 
version (STAI6) 
Women who received HN001 
had significantly lower anxiety 
score in the postpartum 
period. 
(Kelly et al., 2017) Healthy male 
volunteers 
(29 participants) 




No overall effect on mood or 
anxiety. 
  Salivary cortisol No changes 
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   Resting 
electroencephalogra
phy (EEG). 
No effects on sleep quality 





switching, rapid visual 




Basal and stimulated 
cytokine levels by 
ELISA 
No changes observed. 
Subjects were exposed to stress, i.e. a socially evaluated cold pressor test (SECPT). 
Clostridium 
(Yang et al., 2016) Patients with 
laryngeal cancer 





2 weeks before surgery 
 
Heart rate  
 
Prevented the increase before 
surgery 
   Serum CRF levels Prevented the increase before 
surgery 
   Hamilton Anxiety 
Scale (HAMA) 
Relieved the degree of anxiety  
 
Bifidobacterium 








Ameliorate both the 
physiological and 
psychological response to an 
acute stressor, as well as 
longer-term daily self-
reported psychological stress 
   Cognitive 
assessments 
A subtle improvement in 
visuospatial memory 
performance 
   Resting 
electroencephalogra
phy 
An EEG profile consistent with 
improved memory was 
observed 
Combination: Lactobacillus & Bifidobacterium 




(66 men and 
woman) 
L. Helveticus (R0052);  




Lower global severity index, 




   Hospital Anxiety and 
Depression Scale 
(HADS) 
Diminished HADS global 
scores  
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   Perceived Stress 
Scale (PSS) 
No differences 
   Coping Checklist 
(CCL) 
Decreased self-blame score 
and displayed a higher 
problem solving score. 
   24 h urinary free 
cortisol (UFC) 
No differences, although 
probiotics seemed to have 
diminished the urinary free 
cortisol level. 




(20 participants)  
Multispecies probiotic:  
B. bifidum (W23), B. lactis 
(W52), L. acidophilus 
(W37), L. brevis (W63), L. 
casei (W56), L. salivarius 
(W24), L. lactis (W19 and 
W58) 
4-week 
Revised Leiden index 
of depression 
sensitivity scale. 













BB12) or (Streptococcus 
thermophilus and 
Lactobacillus bulgaricus) 
or (Actobacillus casei, 
L. acidophilus, L. 
rhamnosus, L. bulgaricus 
, Bifidobacterium breve, 





Improvement in GHQ. 
  Depression anxiety 
and stress scale 
(DASS) 
Improvement in DASS scores  
   HPA axis activity  
(Akkasheh et al., 
2016) 
 





Probiotic capsule:             






Decreased score compared 




Adults with IBS 
and diarrhea or a 
mixed-stool 








depression (HAD and 
STAI) 
14 of 22 patients in the 
probiotic group had reduction 
in depression scores of 2 
points or more on the Hospital 
Anxiety. Probiotic had no 
significant effect on anxiety. 
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(44 patients) 
   IBS symptoms and 
signs (Birmingham 
IBS score and Bristol 
stool scale) 
Probiotic had no significant 
effect on IBS symptoms 
   Health related 
quality of life (Short 
Form Health Suvery 
(SF)-36) 
Patients in the probiotic group 
had a mean increase in quality 
of life score compared with 
the placebo group 
   Somatization 
(Patient Health 
Questionnaire-15) 
Somatization scores were 
similar in both groups 
(placebo and probiotic) 
   Brain activity (fMRI) Probiotic reduced responses 
to negative emotional stimuli 
in multiple brain areas 
   Blood and urine 
samples 
Probiotic and placebo had 
similar serum markers of 
inflammation, and levels of 
neurotrophins and 
neurotransmitters. Probiotic 
group had reduced urine 
levels of methylamines and 
aromatic amino acids 
metabolites 
   Microbiota analysis Probiotic and placebo had 
similar fecal microbiota 
profiles 
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